Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.

Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
复制标题

DOI:
10.1016/j.bmcl.2022.128629
复制
发表时间:
2022-04-15
影响因子:
2.7
通讯作者:
Nitsche C
Nitsche C
中科院分区:
医学4区
文献类型:
--
作者:
Ullrich S;Ekanayake KB;Otting G;Nitsche C

文献摘要

参考文献

被引文献

相似文献

COVID-19 大流行仍然是一个公共卫生威胁。 SARS-CoV-2 新兴变种的刺突蛋白的多个突变似乎影响了现有疫苗的有效性。人们热切期待特定的抗病毒药物,但它们的功效也可能在新出现的变体中受到损害。最有吸引力的冠状病毒药物靶点之一是主要蛋白酶(Mpro)。一种有前景的具有临床意义的 Mpro 抑制剂是拟肽 nirmatrelvir (PF-07321332)。我们表达了 6 个 SARS-CoV-2 谱系(C.37 Lambda、B.1.1.318、B.1.2、B.1.351 Beta、B.1.1.529 Omicron、P.2 Zeta)的 Mpro,每个谱系都携带非常普遍的错义突变(G15S、T21I、L89F、K90R、P132H、L205V)。酶动力学表明这些 Mpro 变体的催化能力与野生型相似。我们表明 nirmatrelvir 对变异体具有与野生型相似的效力。我们的体外数据表明,特定 Mpro 抑制剂 nirmatrelvir 的功效在当前的 COVID-19 变体中并未受到影响。
The COVID-19 pandemic continues to be a public health threat. Multiple mutations in the spike protein of emerging variants of SARS-CoV-2 appear to impact on the effectiveness of available vaccines. Specific antiviral agents are keenly anticipated but their efficacy may also be compromised in emerging variants. One of the most attractive coronaviral drug targets is the main protease (Mpro). A promising Mpro inhibitor of clinical relevance is the peptidomimetic nirmatrelvir (PF-07321332). We expressed Mpro of six SARS-CoV-2 lineages (C.37 Lambda, B.1.1.318, B.1.2, B.1.351 Beta, B.1.1.529 Omicron, P.2 Zeta), each of which carries a strongly prevalent missense mutation (G15S, T21I, L89F, K90R, P132H, L205V). Enzyme kinetics reveal that these Mpro variants are catalytically competent to a similar degree as the wildtype. We show that nirmatrelvir has similar potency against the variants as the wildtype. Our in vitro data suggest that the efficacy of the specific Mpro inhibitor nirmatrelvir is not compromised in current COVID-19 variants.
DOI: 10.1016/j.cell.2021.09.010
发表时间: 2021-09-30
期刊: Cell
影响因子: 64.5
作者:
Cevik M;Grubaugh ND;Iwasaki A;Openshaw P
通讯作者: Openshaw P
DOI: 10.1016/j.cell.2021.12.032
发表时间: 2022-02-03
期刊: Cell
影响因子: 64.5
作者:
Hoffmann M;Krüger N;Schulz S;Cossmann A;Rocha C;Kempf A;Nehlmeier I;Graichen L;Moldenhauer AS;Winkler MS;Lier M;Dopfer-Jablonka A;Jäck HM;Behrens GMN;Pöhlmann S
通讯作者: Pöhlmann S
DOI: 10.1016/j.cell.2021.01.044
发表时间: 2021-03-04
期刊: Cell
影响因子: 64.5
作者:
Grubaugh ND;Hodcroft EB;Fauver JR;Phelan AL;Cevik M
通讯作者: Cevik M
DOI: 10.1021/bi1002585
发表时间: 2010-05-25
期刊: BIOCHEMISTRY
影响因子: 2.9
作者:
Barrila, Jennifer;Gabelli, Sandra B.;Bacha, Usman;Amzel, L. Mario;Freire, Ernesto
通讯作者: Freire, Ernesto
DOI: 10.1016/j.antiviral.2013.08.015
发表时间: 2013-10
期刊: Antiviral research
影响因子: 7.6
作者:
Hilgenfeld R;Peiris M
通讯作者: Peiris M